BR112023003432A2 - Regime de tratamento para o tratamento de doenças autoimunes - Google Patents

Regime de tratamento para o tratamento de doenças autoimunes

Info

Publication number
BR112023003432A2
BR112023003432A2 BR112023003432A BR112023003432A BR112023003432A2 BR 112023003432 A2 BR112023003432 A2 BR 112023003432A2 BR 112023003432 A BR112023003432 A BR 112023003432A BR 112023003432 A BR112023003432 A BR 112023003432A BR 112023003432 A2 BR112023003432 A2 BR 112023003432A2
Authority
BR
Brazil
Prior art keywords
treatment
autoimmune diseases
regime
new
treatment regimen
Prior art date
Application number
BR112023003432A
Other languages
English (en)
Portuguese (pt)
Inventor
Boschert Ursula
Wiederman Urs
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR112023003432A2 publication Critical patent/BR112023003432A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
  • Application Of Or Painting With Fluid Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112023003432A 2020-09-10 2021-09-10 Regime de tratamento para o tratamento de doenças autoimunes BR112023003432A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062706795P 2020-09-10 2020-09-10
US202062706819P 2020-09-11 2020-09-11
US202063198971P 2020-11-25 2020-11-25
US202063199265P 2020-12-16 2020-12-16
US202163149196P 2021-02-12 2021-02-12
US202163175318P 2021-04-15 2021-04-15
PCT/EP2021/074928 WO2022053608A1 (en) 2020-09-10 2021-09-10 Novel treatment regimen for the treatment of autoimmune disorders

Publications (1)

Publication Number Publication Date
BR112023003432A2 true BR112023003432A2 (pt) 2023-03-21

Family

ID=78080246

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023003432A BR112023003432A2 (pt) 2020-09-10 2021-09-10 Regime de tratamento para o tratamento de doenças autoimunes

Country Status (10)

Country Link
US (5) US20240226284A1 (https=)
EP (1) EP4210710A1 (https=)
JP (1) JP2023541877A (https=)
KR (1) KR20230066402A (https=)
AU (1) AU2021342333A1 (https=)
BR (1) BR112023003432A2 (https=)
CA (1) CA3194812A1 (https=)
IL (1) IL301246A (https=)
MX (1) MX2023002843A (https=)
WO (1) WO2022053608A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023003432A2 (pt) 2020-09-10 2023-03-21 Merck Patent Gmbh Regime de tratamento para o tratamento de doenças autoimunes
AU2023293707A1 (en) 2022-06-15 2025-01-23 Vektor Pharma Tf Gmbh Sublingual formulation of anticancer compound for use in the treatment of autoimmune neurodegenerative diseases

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3273787D1 (en) 1981-02-04 1986-11-20 Japan Found Cancer Human interferon-beta gene
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
JPS62153300A (ja) 1985-12-26 1987-07-08 Teijin Ltd ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法
US5106837A (en) 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DE68926888T2 (de) 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US4964848A (en) 1988-06-27 1990-10-23 Bloom Philip M Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ES2145744T5 (es) 1991-01-18 2008-02-01 Amgen Inc. Procedimientos para tratar las enfermedades inducidas por el factor de necrosis tumoral.
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
EP0801571B1 (en) 1994-12-22 2002-09-04 Ortho Pharmaceutical Corporation Soluble 2-chloro-2'-deoxyadenosine formulations
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US6800616B2 (en) 1998-02-26 2004-10-05 Supergen, Inc. Treatment of HIV infections
EE05214B1 (et) 1998-04-28 2009-10-15 Applied Research Systems ARS Holding N.V. Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
BR9915548A (pt) 1998-10-16 2001-08-14 Biogen Inc Proteìnas de fusão de interferon-beta e usos
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
FR2792480B1 (fr) 1999-04-19 2001-06-15 France Telecom Systeme de mise en oeuvre de services telephoniques
WO2000064918A1 (en) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
US7754855B1 (en) 1999-07-13 2010-07-13 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
EP1556400B1 (en) 2002-09-25 2013-05-01 Brigham Young University Method for the preparation of 2-halo-2 -deoxyadenosine compounds from 2 -deoxyguanosine
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
WO2004075903A1 (en) 2003-02-25 2004-09-10 Applied Research Systems Ars Holding N.V. Combined use of ribavirin and interferon beta in demyelinating diseases
WO2004087100A2 (en) 2003-03-28 2004-10-14 Ivax Corporation Cladribine formulations for improved oral and transmucosal delivery
DK2272503T3 (da) 2003-03-28 2013-05-21 Ares Trading Sa Orale formuleringer af cladribin
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
MXPA04010902A (es) * 2004-11-03 2006-05-08 Alvaro Raul Lara Rodriguez Vacuna recombinante a partir de las proteinas ge, gi y gb del virus de varicela zoster como tratamiento y prevencion de esclerosis multiple.
EP2275110B1 (en) 2004-12-22 2013-07-10 Merck Serono SA Cladribine regimen for treating Multiple Sclerosis
WO2007135172A2 (en) 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis
WO2017035357A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
AR113906A1 (es) 2017-11-24 2020-06-24 Merck Patent Ges Mit Beschraenkter Haftung Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple
BR112023003432A2 (pt) 2020-09-10 2023-03-21 Merck Patent Gmbh Regime de tratamento para o tratamento de doenças autoimunes

Also Published As

Publication number Publication date
US20260115278A1 (en) 2026-04-30
US20260069681A1 (en) 2026-03-12
CA3194812A1 (en) 2022-03-17
US20240226284A1 (en) 2024-07-11
US20240335529A1 (en) 2024-10-10
EP4210710A1 (en) 2023-07-19
WO2022053608A1 (en) 2022-03-17
IL301246A (en) 2023-05-01
JP2023541877A (ja) 2023-10-04
AU2021342333A1 (en) 2023-04-06
MX2023002843A (es) 2023-03-31
KR20230066402A (ko) 2023-05-15
US12539329B2 (en) 2026-02-03
US20240374715A1 (en) 2024-11-14
US12533408B2 (en) 2026-01-27

Similar Documents

Publication Publication Date Title
MX2025007468A (es) Composiciones y metodos para el manejo de trastornos
BR112021022789A2 (pt) Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a
BR112022009216A2 (pt) Métodos e composições para tratar um distúrbio associado a angiotensinogênio (agt)
BR112018071347A2 (pt) moduladores de nlrp3
BR112023003432A2 (pt) Regime de tratamento para o tratamento de doenças autoimunes
ECSP20024210A (es) Uso de inhibidores de p38 para reducir la expresión de dux4
BR112022019932A2 (pt) Composições para saúde metabólica
MX2022004143A (es) Compuesto que tiene actividad inhibidora de brd4, su método de preparación y su uso.
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
MX2021015338A (es) Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma.
MX391627B (es) Aplicación cuantitativa periorbital de fármacos oftalmológicos.
BR112022020020A2 (pt) Métodos de tratamento da doença do coronavírus 2019
MX2021008941A (es) Moduladores gpr35.
CL2023001580A1 (es) Uso de roluperidona para tratar síntomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroprotección
MX2023000763A (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas.
BR112017004729A2 (pt) processo de tratamento de doenças causadas por metástase óssea, medicamentos para as mesmas e processo de previsão do resultado clínico de tratamento de doenças causadas por metástase óssea
Esmail The diagnosis and management of Parkinson’s disease
CO2024007361A2 (es) Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
BR112022003539A2 (pt) Terapia enzimática com cistationina beta-sintase para tratamento de níveis elevados de homocisteína
AR092842A1 (es) Tratamiento de enfermedades inflamatorias oculares usando laquinimod
BR112022012365A2 (pt) Tratamento de lesão cerebral traumática leve
BR112015029299A2 (pt) subpopulação de monócitos humanos para tratamento de doenças e distúrbios oculares
MX2022010093A (es) Tafoxiparina para el tratamiento de la preeclampsia.
PY2013134A (es) Métodos para el tratamiento de enfermedades relacionadas con tnfa
Chazova et al. Education and self-education of the patients is an important step towards increasing patients acceptance of therapy